Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLx-2101 in Patients With Hypertension
NCT00562614Phase 2Completed
- Sponsor
- Retension Pharmaceuticals
- Start
- Jun 2007
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertension (HTN) comparing SLx-2101 Sequence with Placebo Sequence (2 arms). Primary endpoints: Peripheral systolic and diastolic blood pressures at 14 days, Heart rate at 14 days and 1 more. Started Jun 2007; status: completed.
02
Drugs
slx-2101
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00562614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562614.